Why Now Is The Perfect Time For Me To Buy GlaxoSmithKline plc And Dechra Pharmaceuticals plc

These 2 stocks look set to post stunning gains: GlaxoSmithKline plc (LON: GSK) and Dechra Pharmaceuticals plc (LON: DPH)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

With market volatility being relatively high at the present time, buying pharmaceutical companies could prove to be a wise move. A key reason for this is that their business models are a lot less dependent upon the performance of the wider economy that for most stocks, since the development of new drugs and their sales tends to be somewhat detached from the macroeconomic outlook for the wider economy. As such, shares in GlaxoSmithKline (LSE: GSK) and Dechra (LSE: DPH) have held up better than the wider index during the last month, with them being down by 5% each versus almost 8% for the FTSE 100.

However, there is much more to both stocks above and beyond their relatively low correlation with the performance of the wider economy. Certainly, the pharmaceutical industry is a boom/bust space, with the loss of patents on blockbuster drugs having a negative impact on sales and profitability in the short run. There is, though, excellent growth potential on offer and, in this regard, both GlaxoSmithKline and Dechra are set to perform exceptionally well.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

For example, GlaxoSmithKline is forecast to increase its earnings by 12% next year as it continues to make encouraging progress regarding cost savings and other efficiencies. This puts the stock on a price to earnings growth (PEG) ratio of just 1.3, which indicates that its share price could be set to move upwards at a brisk pace. Similarly, Dechra is expected to increase its bottom line by 11% next year and, although it trades on a PEG ratio of 2, its excellent track record of growth (earnings have increased at an annualised rate of 11% during the last four years) indicates that it is a relatively reliable performer that is worthy of a premium.

Furthermore, Dechra also has a very low beta of 0.4. This means that for every 1% move in the level of the wider index, Dechra’s share price is expected to change by just 0.4%. And, with the short to medium term prospects for the FTSE 100 being highly uncertain, this could be a major positive for investors. Meanwhile, GlaxoSmithKline offers a yield of over 6% at the present time and, while dividends are not due to rise over the next couple of years, such income prospects are likely to provide considerable support for the company’s share price so that even if the wider index falls, GlaxoSmithKline’s share price should hold up well.

Clearly, the share price performance of the two companies in recent years has differed significantly. While Dechra has soared by 124%, GlaxoSmithKline is up by just 8%. However, looking ahead they both appear to offer strong growth prospects at a reasonable price and, while Dechra’s yield of 1.8% is somewhat disappointing, it has a payout ratio of just 42% and this indicates that its dividends could rise substantially over the medium to long term. Equally, GlaxoSmithKline’s fall in profitability of 14% in the last three years may be disappointing but, with a bright medium-term future, it appears to be a perfect moment to buy a slice of the company alongside Dechra.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy woman with excess weight smiling and dancing alone in sports clothes
Investing Articles

Top British growth stocks for May

We asked our freelance writers to share the top growth stocks they’d buy in May, which included miners and musical…

Read more »

Electric cars charging at a charging station
Investing Articles

A cheap UK share I’d buy for the electric vehicle revolution

This cheap UK share has collapsed in value since I bought last year. But here's why I'm thinking of buying…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

3 distressed stocks with huge potential that I’m considering for my portfolio!

These three distressed stocks have performed badly in 2022, but that doesn't mean they won't recover. Here's why I'm considering…

Read more »

Luxury inside of NIO car
Investing Articles

Here’s why I’ve just bought NIO shares!

I've recently bought NIO shares, despite the stock being down nearly 80% over the past year. Here's why!

Read more »

Mature people enjoying time together during road trip
Investing Articles

Is now the time to buy Tesla shares?

Tesla's share price has fallen in 2022 and so has its valuation. Edward Sheldon looks at whether this is a…

Read more »

A graph made of neon tubes in a room
Investing Articles

Are Woodbois shares worth me buying at 4.7p?

Jon Smith considers the recent surge in price for Woodbois shares, and wonders if the move lower last week represents…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

How I’d generate a passive income for life with just £20 a week

Dividend shares can be an excellent way to earn a passive income for life. Our writer discusses a plan to…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Hargreaves Lansdown investors are buying these cheap FTSE 100 shares. Should I?

Paul Summers takes a closer look at two cheap FTSE 100 stocks that were proving very popular with investors last…

Read more »